HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients.
Identifieur interne : 000268 ( PubMed/Corpus ); précédent : 000267; suivant : 000269HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients.
Auteurs : D. Wong ; M. Littlejohn ; L. Yuen ; K. Jackson ; H. Mason ; J. Bayliss ; G. Rosenberg ; A. Gaggar ; K. Kitrinos ; M. Subramanian ; P. Marcellin ; M. Buti ; H L A. Janssen ; E. Gane ; S. Locarnini ; A. Thompson ; P A RevillSource :
- Alimentary pharmacology & therapeutics [ 1365-2036 ] ; 2017.
Abstract
Hepatitis B e antigen (HBeAg) seroconversion is a treatment endpoint for HBeAg-positive CHB, and a necessary precursor to HBsAg loss. Biomarkers that predict serological outcomes would be useful.
DOI: 10.1111/apt.14362
PubMed: 29023803
Links to Exploration step
pubmed:29023803Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients.</title>
<author><name sortKey="Wong, D" sort="Wong, D" uniqKey="Wong D" first="D" last="Wong">D. Wong</name>
<affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Littlejohn, M" sort="Littlejohn, M" uniqKey="Littlejohn M" first="M" last="Littlejohn">M. Littlejohn</name>
<affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Yuen, L" sort="Yuen, L" uniqKey="Yuen L" first="L" last="Yuen">L. Yuen</name>
<affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Jackson, K" sort="Jackson, K" uniqKey="Jackson K" first="K" last="Jackson">K. Jackson</name>
<affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Mason, H" sort="Mason, H" uniqKey="Mason H" first="H" last="Mason">H. Mason</name>
<affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bayliss, J" sort="Bayliss, J" uniqKey="Bayliss J" first="J" last="Bayliss">J. Bayliss</name>
<affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Rosenberg, G" sort="Rosenberg, G" uniqKey="Rosenberg G" first="G" last="Rosenberg">G. Rosenberg</name>
<affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gaggar, A" sort="Gaggar, A" uniqKey="Gaggar A" first="A" last="Gaggar">A. Gaggar</name>
<affiliation><nlm:affiliation>Gilead Sciences, Foster City, CA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kitrinos, K" sort="Kitrinos, K" uniqKey="Kitrinos K" first="K" last="Kitrinos">K. Kitrinos</name>
<affiliation><nlm:affiliation>Gilead Sciences, Foster City, CA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Subramanian, M" sort="Subramanian, M" uniqKey="Subramanian M" first="M" last="Subramanian">M. Subramanian</name>
<affiliation><nlm:affiliation>Gilead Sciences, Foster City, CA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Marcellin, P" sort="Marcellin, P" uniqKey="Marcellin P" first="P" last="Marcellin">P. Marcellin</name>
<affiliation><nlm:affiliation>Hôpital Beaujon, University of Paris, Clichy, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Buti, M" sort="Buti, M" uniqKey="Buti M" first="M" last="Buti">M. Buti</name>
<affiliation><nlm:affiliation>Liver Unit, Vall d'Hebron (Ciberehd) University Hospital, Barcelona, Spain.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Janssen, H L A" sort="Janssen, H L A" uniqKey="Janssen H" first="H L A" last="Janssen">H L A. Janssen</name>
<affiliation><nlm:affiliation>Toronto Center for Liver Diseases, Toronto Western and General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gane, E" sort="Gane, E" uniqKey="Gane E" first="E" last="Gane">E. Gane</name>
<affiliation><nlm:affiliation>New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Locarnini, S" sort="Locarnini, S" uniqKey="Locarnini S" first="S" last="Locarnini">S. Locarnini</name>
<affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Thompson, A" sort="Thompson, A" uniqKey="Thompson A" first="A" last="Thompson">A. Thompson</name>
<affiliation><nlm:affiliation>Department of Gastroenterology, St. Vincent's Hospital, Melbourne, Vic., Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Revill, P A" sort="Revill, P A" uniqKey="Revill P" first="P A" last="Revill">P A Revill</name>
<affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:29023803</idno>
<idno type="pmid">29023803</idno>
<idno type="doi">10.1111/apt.14362</idno>
<idno type="wicri:Area/PubMed/Corpus">000268</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000268</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients.</title>
<author><name sortKey="Wong, D" sort="Wong, D" uniqKey="Wong D" first="D" last="Wong">D. Wong</name>
<affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Littlejohn, M" sort="Littlejohn, M" uniqKey="Littlejohn M" first="M" last="Littlejohn">M. Littlejohn</name>
<affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Yuen, L" sort="Yuen, L" uniqKey="Yuen L" first="L" last="Yuen">L. Yuen</name>
<affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Jackson, K" sort="Jackson, K" uniqKey="Jackson K" first="K" last="Jackson">K. Jackson</name>
<affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Mason, H" sort="Mason, H" uniqKey="Mason H" first="H" last="Mason">H. Mason</name>
<affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bayliss, J" sort="Bayliss, J" uniqKey="Bayliss J" first="J" last="Bayliss">J. Bayliss</name>
<affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Rosenberg, G" sort="Rosenberg, G" uniqKey="Rosenberg G" first="G" last="Rosenberg">G. Rosenberg</name>
<affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gaggar, A" sort="Gaggar, A" uniqKey="Gaggar A" first="A" last="Gaggar">A. Gaggar</name>
<affiliation><nlm:affiliation>Gilead Sciences, Foster City, CA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kitrinos, K" sort="Kitrinos, K" uniqKey="Kitrinos K" first="K" last="Kitrinos">K. Kitrinos</name>
<affiliation><nlm:affiliation>Gilead Sciences, Foster City, CA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Subramanian, M" sort="Subramanian, M" uniqKey="Subramanian M" first="M" last="Subramanian">M. Subramanian</name>
<affiliation><nlm:affiliation>Gilead Sciences, Foster City, CA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Marcellin, P" sort="Marcellin, P" uniqKey="Marcellin P" first="P" last="Marcellin">P. Marcellin</name>
<affiliation><nlm:affiliation>Hôpital Beaujon, University of Paris, Clichy, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Buti, M" sort="Buti, M" uniqKey="Buti M" first="M" last="Buti">M. Buti</name>
<affiliation><nlm:affiliation>Liver Unit, Vall d'Hebron (Ciberehd) University Hospital, Barcelona, Spain.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Janssen, H L A" sort="Janssen, H L A" uniqKey="Janssen H" first="H L A" last="Janssen">H L A. Janssen</name>
<affiliation><nlm:affiliation>Toronto Center for Liver Diseases, Toronto Western and General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gane, E" sort="Gane, E" uniqKey="Gane E" first="E" last="Gane">E. Gane</name>
<affiliation><nlm:affiliation>New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Locarnini, S" sort="Locarnini, S" uniqKey="Locarnini S" first="S" last="Locarnini">S. Locarnini</name>
<affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Thompson, A" sort="Thompson, A" uniqKey="Thompson A" first="A" last="Thompson">A. Thompson</name>
<affiliation><nlm:affiliation>Department of Gastroenterology, St. Vincent's Hospital, Melbourne, Vic., Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Revill, P A" sort="Revill, P A" uniqKey="Revill P" first="P A" last="Revill">P A Revill</name>
<affiliation><nlm:affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Alimentary pharmacology & therapeutics</title>
<idno type="eISSN">1365-2036</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Hepatitis B e antigen (HBeAg) seroconversion is a treatment endpoint for HBeAg-positive CHB, and a necessary precursor to HBsAg loss. Biomarkers that predict serological outcomes would be useful.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">29023803</PMID>
<DateCreated><Year>2017</Year>
<Month>10</Month>
<Day>12</Day>
</DateCreated>
<DateRevised><Year>2017</Year>
<Month>10</Month>
<Day>12</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2036</ISSN>
<JournalIssue CitedMedium="Internet"><PubDate><Year>2017</Year>
<Month>Oct</Month>
<Day>11</Day>
</PubDate>
</JournalIssue>
<Title>Alimentary pharmacology & therapeutics</Title>
<ISOAbbreviation>Aliment. Pharmacol. Ther.</ISOAbbreviation>
</Journal>
<ArticleTitle>HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients.</ArticleTitle>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/apt.14362</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Hepatitis B e antigen (HBeAg) seroconversion is a treatment endpoint for HBeAg-positive CHB, and a necessary precursor to HBsAg loss. Biomarkers that predict serological outcomes would be useful.</AbstractText>
<AbstractText Label="AIM" NlmCategory="OBJECTIVE">To evaluate the utility of measuring HBeAg levels for predicting HBeAg seroconversion and HBsAg loss under long-term tenofovir (TDF) therapy.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">A total of 266 patients were enrolled into a phase III study of TDF vs adefovir (ADV) for 48 weeks in HBeAg-positive patients, followed by open-label TDF up to 384 weeks. Serum HBeAg levels were measured for subjects with samples available at both baseline and week 24 of treatment (n = 200). Analysis compared subjects who achieved HBeAg seroconversion by week 384 vs no HBeAg seroconversion.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">HBeAg seroconversion rate was 52% by week 384. Time to HBeAg seroconversion was 80 weeks (IQR: 36-162). HBeAg decline at week 24 was associated with HBeAg seroconversion (1.63 vs 0.90 log10 PEIU/mL, P = .002). The optimal threshold for identifying HBeAg seroconversion was HBeAg decline ≥2.2 log10 PEIU/mL at week 24, with HBeAg seroconversion achieved by 76% of patients, compared to 44% if HBeAg decline <2.2 log10 (P < .0001). HBeAg decline ≥2.2 log10 PEIU/mL at week 24 was associated with HBsAg loss in genotype A or D patients (38% vs 15%, P = .03). Precore/basal core promotor variants were associated with lower baseline HBeAg levels, but not HBeAg seroconversion.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Decline in HBeAg levels by week 24 was associated with HBeAg seroconversion and HBsAg loss in HBeAg-positive chronic hepatitis B patients treated with long-term TDF.</AbstractText>
<CopyrightInformation>© 2017 John Wiley & Sons Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wong</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0003-1490-0547</Identifier>
<AffiliationInfo><Affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Gastroenterology, St. Vincent's Hospital, Melbourne, Vic., Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Littlejohn</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Yuen</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jackson</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mason</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bayliss</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rosenberg</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gaggar</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Gilead Sciences, Foster City, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kitrinos</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Gilead Sciences, Foster City, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Subramanian</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Gilead Sciences, Foster City, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Marcellin</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Hôpital Beaujon, University of Paris, Clichy, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Buti</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Liver Unit, Vall d'Hebron (Ciberehd) University Hospital, Barcelona, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Janssen</LastName>
<ForeName>H L A</ForeName>
<Initials>HLA</Initials>
<AffiliationInfo><Affiliation>Toronto Center for Liver Diseases, Toronto Western and General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gane</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Locarnini</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Thompson</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Gastroenterology, St. Vincent's Hospital, Melbourne, Vic., Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Revill</LastName>
<ForeName>P A</ForeName>
<Initials>PA</Initials>
<AffiliationInfo><Affiliation>Division of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2017</Year>
<Month>10</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Aliment Pharmacol Ther</MedlineTA>
<NlmUniqueID>8707234</NlmUniqueID>
<ISSNLinking>0269-2813</ISSNLinking>
</MedlineJournalInfo>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year>
<Month>08</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2017</Year>
<Month>09</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2017</Year>
<Month>09</Month>
<Day>14</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2017</Year>
<Month>10</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2017</Year>
<Month>10</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>10</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>aheadofprint</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">29023803</ArticleId>
<ArticleId IdType="doi">10.1111/apt.14362</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000268 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000268 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:29023803 |texte= HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:29023803" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |